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Abstract
Background and objectives
We tested the hypothesis that single nucleotide polymorphisms (SNPs) in the calcium-sensing receptor
(CASR) alter the response to the calcimimetic cinacalcet.
Design, setting, participants, & measurements
We analyzed DNA samples in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events
(EVOLVE) trial, a randomized trial comparing cinacalcet to placebo on a background of usual care. Of the
3883 patients randomized, 1919 (49%) consented to DNA collection, and samples from 1852 participants
were genotyped for 18 CASR polymorphisms. The European ancestry (EA; n=1067) and African ancestry
(AfAn; n=405) groups were assessed separately. SNPs in CASR were tested for their association with
biochemical measures of mineral metabolism at baseline, percent change from baseline to 20 weeks, and
risk of clinical fracture as dependent variables.
Results
There were modest associations of CASR SNPs with increased baseline serum parathyroid hormone and
bone alkaline phosphatase primarily with the minor allele in the EA group (all P≤0.03), but not in the AfAn
sample. In contrast, there was a modest association of decreased baseline serum calcium and FGF23 with
CASR SNPs (P=0.04) primarily with the minor allele in the AfAn but not in the EA sample. The minor
allele of two SNPs was associated with decreased percent reduction in parathyroid hormone from baseline
to 20 weeks in the EA population (P<0.04) and this was not altered with cinacalcet. In both EA and AfAn,
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the same SNP (rs9740) was associated with decreased calcium with cinacalcet treatment (EA and AfAn
P≤0.03). Three SNPs in high linkage disequilibrium were associated with a higher risk of clinical fracture
that was attenuated by cinacalcet treatment in the EA sample (P<0.04).
Conclusions
These modest associations, if validated, may provide explanations for differences in CKD–mineral bone
disorder observed in EA and AfAn populations, and for differential biochemical responses to
calcimimetics.
Keywords: human genetics, calcium sensing receptor, fracture, FGF23, single nucleotide polymorphisms,
Alkaline Phosphatase, Alleles, calcium, Chronic Kidney Disease-Mineral and Bone Disorder, Cinacalcet
Hydrochloride, DNA, Genotype, Humans, Linkage Disequilibrium, Minerals, parathyroid hormone,
Polymorphism, Single Nucleotide, Receptors, Calcium-Sensing, renal dialysis
Introduction
Complications of moderate to advanced CKD include a variety of disorders of mineral metabolism.
Associated clinical manifestations, termed CKD–mineral bone disorder (CKD-MBD [1,2]), include bone
disease (with an increased risk of fracture), cardiomyopathy, anemia, pruritus, extraskeletal calcification,
and increased risks of mortality, heart failure, and other cardiovascular events (3,4). Treatment of secondary
hyperparathyroidism can attenuate many of these manifestations. Treatment options include the use of
pharmacologic doses of 1,25 dihydroxy vitamin D (calcitriol) or related analogs, the calcimimetic
cinacalcet, and parathyroidectomy. Optimizing the approach for patient care through genomics to predict
individual risk may help clinicians choose appropriate treatments.
Calcimimetics are allosteric activators of the calcium-sensing receptor (CASR). Cinacalcet
(Sensipar/Mimpara) has been shown to lower serum parathyroid hormone (PTH), calcium, and phosphorus
in patients undergoing dialysis (5,6). In the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular
Events (EVOLVE) trial (7,8), 3883 individuals were randomized to either cinacalcet or placebo in addition
to standard of care treatments, which typically included phosphate binders and calcitriol or its analogs. In
the trial, 24% of patients in the placebo arm and 12% of patients in the cinacalcet arm had severe
unremitting hyperparathyroidism, demonstrating that some patients did not respond to cinacalcet treatment
(7). Other studies have demonstrated that blacks with CKD have higher PTH concentrations compared with
other races, suggesting altered response to pharmacotherapy (9,10). One possible explanation for these
observations is genetic variability. We therefore examined the association of genetic polymorphisms in the
CASR and vitamin D receptor (VDR) genes and biochemical and clinical outcomes using stored
biospecimens and clinical trial outcomes data from the EVOLVE trial.
Materials and Methods
Patients enrolled in the EVOLVE trial (7,8) were asked to consent for collection of DNA at the baseline
visit. The EVOLVE trial was a global trial with individuals enrolled from 22 countries (8). Of the 3883
participants enrolled in the EVOLVE trial, 1919 (49%) consented to have DNA collected. The blood
samples were processed by the central study laboratory (Covance, Princeton, NJ), and before release to
Indiana University the trial sponsor, Amgen, confirmed appropriate institutional review board approval at
each site for DNA collection, and separate informed consent for DNA collection and use. After DNA
extraction, 1852 (97%) of samples were of initial adequate quality to be genotyped.
Genotyping
On the basis of previously published literature, one single nucleotide polymorphism (SNP) in VDR (11,12)
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and 18 SNPs in CASR (13–16) were genotyped to ensure the entire gene could be evaluated for evidence of
association. For quality assessment, additional SNPs were genotyped on the X and Y chromosomes to
confirm self-reported sex. Only samples with an SNP genotype rate >90% (seven samples excluded), and
X- and Y-linked SNPs confirming self-reported sex (33 samples excluded) were retained. The remaining
1812 samples were included for analyses.
Race provided by each EVOLVE trial participant was used for race-based group assignments. Only the
European ancestry (EA) and African ancestry (AfAn) groups were analyzed because of small numbers and
heterogeneity in the other groups. There was no significant deviation from Hardy–Weinberg equilibrium for
any SNPs in either racial group (all P>0.01). Linkage disequilibrium (LD) was estimated in each race-
based group (Figure 1, A and B) and compared with the appropriate HapMap samples to ensure that the
selected SNPs provided complete coverage of the gene.
Statistical Analyses
Because of admixture within the AfAn sample and differences in allele frequency between the EA and
AfAn samples, all analyses were conducted in these cohorts separately. All nongenetic analyses and
phenotype calculations were performed in SAS v9.4. We log-transformed all baseline laboratory variables
before inference testing. Because the underlying genetic model was unknown, additive genetic models
implemented in PLINK v1.07 (http://pngu.mgh.harvard.edu/purcell/plink/) (17) were used in all genetic
analyses. This model assumes a similar increase (or decrease) in phenotype value for each copy of an
allele. Because of the correlation of SNPs within CASR, we did not correct for the number of SNPs tested.
The phenotypes examined in this study were chosen on the basis of previously reported literature. Initial
analyses report the nominal association results and secondary analyses considered a correction for the six
phenotypes, resulting in a corrected α=0.008.
We employed linear regression including SNPs in all models and considered covariates individually, using
forward stepwise regression with a stay criterion set at P=0.10. Covariates tested in this initial phase
included age, sex, baseline calcium-containing phosphate binder use, and natural log-transformed baseline
values of prior duration of dialysis (months), vitamin D use, bone-specific alkaline phosphatase (BALP)
(nanogram per milliliter), intact PTH (picogram per milliliter), phosphorous (milligram per deciliter), and
serum N-telopeptide (nanomole bone collagen equivalents per liter), excluding the baseline measure of
interest. We first tested for association of SNPs in the CASR and VDR genes with baseline laboratory values
for calcium (corrected for albumin), PTH, fibroblast growth factor 23 (FGF23), phosphate, and BALP after
adjustment for covariates significantly associated (P<0.10) with the modeled dependent variable. To
increase power, residuals obtained from regression models implementing the appropriate covariates were
employed in further genetic analysis. /because of the skewed baseline values, the natural log of all
laboratory values was used for baseline analyses to obtain approximately normal distributions.
In the EVOLVE trial, samples were obtained at week 20, 52, and 104. At 20 weeks, >90% of patients
remained on their original treatment assignment, and the majority of patients had samples drawn at this
time point. We therefore tested for association of the SNPs with percent change in calcium, phosphorus,
PTH, and FGF23 from baseline to 20 weeks. Age and baseline values were included in all percent change
analyses, regardless of P value, and residuals were computed for each variable as described above. A linear
regression model was employed in PLINK, using the residuals. Randomized treatment and an interaction
term for SNP×randomized treatment were included in this step, to determine if SNP genotype altered the
response to cinacalcet in the treatment group compared with the placebo group. Finally, given that
secondary hyperparathyroidism alters bone metabolism and CASR is expressed in bone (18), we tested for
association of SNPs in CASR and VDR with risk of fracture using logistic regression models in PLINK
(17). Forward logistic regression analyses were implemented as above, considering covariates previously
Calcium-Sensing Receptor Genotype and Response to Cinacalcet in Patie... https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5498355/?report=printable
3 of 20 5/24/2019, 3:32 PM
shown to be associated with cardiovascular events and fracture risk in the EVOLVE trial (19,20).
Covariates and randomized treatment were included in the logistic regression model in PLINK. As
described above, treatment and an interaction term for SNP×treatment were included to test if fracture
outcome differed by SNP, in the presence of treatment.
Results
Baseline characteristics of the EA and AfAn patients with DNA samples compared with the individuals of
other ancestry and the entire EVOLVE trial are shown in Table 1. A total of 59% of participants with DNA
were EA (n=1067) and 22% were AfAn (n=405). Overall, 37.7% of the samples were collected from
individuals in the United States, 4.3% from Canada, 33.9% from Europe, 22.8% from Latin America, and
the remaining from other geographical regions.
Summary data for SNPs in CASR and VDR are provided in Supplemental Table 1 and Tables 2 and 3. All
SNPs had a missing rate of ≤0.2%. Minor allele frequencies (MAF) in both the EA and AfAn samples were
comparable to the MAF of white Europeans in Utah, Yorubans in Ibadan (Nigeria), and AfAn in the
Southwest HapMap samples in the SNP Database hosted by the National Center for Biotechnology
Information. Because of the limited power to detect association, SNPs with MAF <0.05 within each racial
group were excluded from analyses. The LD plots for each racial group are shown in Figure 1. There were
no significant associations with the VDR SNP and any phenotype (all P>0.2), so only CASR results are
presented.
Associations of CASR SNPs with Baseline and Percent Change in CKD-MBD Laboratory
Values
Tables 2 and 3 show associations of CASR SNPs with baseline laboratory values. In the EA population, the
strongest associations were observed with the missense variant rs1042636 (R990G) and baseline serum
PTH (P<0.01; AA genotype; n=937, mean-±-SD: 813.6±1123.4 versus AG/GG n=148, 904.6±178.8
pg/ml), as well as the missense polymorphism rs1801725 (A986S) with baseline serum phosphate (P=0.03;
GG genotype n=760, 6.5±2.2 versus GT/TT n=326, 6.7±0.9 mg/dl), and baseline serum PTH (P=0.02; GG
genotype 940.3±697.5 versus GT/TT 871.7±925.8 pg/ml). In the AfAn population, neither of these SNPs
were associated with baseline laboratory values (P>0.06); for the remaining CASR SNPs, the strongest
association in the AfAn population was observed with rs1393199 and baseline phosphorus (P<0.001; AA
genotype 6.2±1.15 versus AC/CC 6.5±1.17 mg/dl) and rs4300957 and baseline calcium (P=0.01; CC
genotype n=328, 9.6±1.09 versus CT/TT n=85, 9.8±0.28 mg/dl). Modest associations were also observed
with other SNPs and baseline BALP in the EA population (P<0.02) and baseline FGF23 and calcium in the
AfAn population (P≤0.04).
The association of the CASR SNPs and percent change in PTH, phosphorus, and FGF23 from baseline to
week 20 was examined, adjusted for baseline covariates significantly associated with each biochemical
variable (Supplemental Tables 2 and 3). One extreme value of FGF23 change was winsorized to the 90th
percentile value of 700. As seen in Figure 2, there was a modest association of rs937627 genotype with
percent change in PTH in the EA population (Figure 2A; P=0.04), but no significant interaction with
treatment (P=0.06). There was no association of CASR SNPs with changes in FGF23 or phosphorus (all
P≥0.08). In contrast, in the AfAn population there was an interaction of rs203699 genotype and treatment
for percent change in FGF23; treated individuals homozygous for the major allele had a negative percent
change compared with individuals with at least one copy of the minor allele, who had positive values (
Figure 2B; P=0.01). There was also an interaction of rs1393199 and treatment for percent change in
calcium; homozygotes for the major allele had a greater decrease in response to cinacalcet (rs1393199;
P=0.04). One SNP rs9740 demonstrated an interaction between genotype and treatment for percent change
in calcium in both the EA (P=0.03; Figure 2C) and AfAn (P=0.02; Figure 2D) populations: homozygotes
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for the major allele had a greater decrease in response to cinacalcet.
Associations of CASR SNPs with Fractures
We assessed association of CASR and the VDR SNP genotypes and a clinical (symptomatic) fracture that
occurred after randomization in the EVOLVE trial. There was no significant association of any of the SNPs
and fracture in the AfAn population (all P>0.11). However, in the EA population, there was an association
of three SNPs in CASR (rs4678044, rs4300957, and rs7647446), all in high LD (pairwise r ≥0.89), and the
risk of fracture (all P<0.04) adjusted for history of fracture, sex, and natural log of intact PTH. Treatment
was included in the model as a main effect for both populations. For these three SNPs, the odds of
experiencing a fracture increased by approximately 45% for each copy of the minor allele. Figure 3
demonstrates this finding for SNP rs7647446: patients homozygous for the minor allele AA had an
increased association of higher risk of fracture that was reduced with cinacalcet treatment (treatment
adjusted odds ratio, 0.47; 95% confidence interval, 0.24 to 0.93; P=0.03). There was no association of
fracture with the VDR SNP in either population (both P>0.24).
When considering correction for the evaluation of six phenotypes, only baseline changes of serum PTH in
the EA population (rs1042636), as well as serum phosphorous (rs1393199) and calcium (rs4300957) in the
AfAn population meet the threshold of P<0.01.
Discussion
This study is the largest to date to examine polymorphisms of the CASR gene in patients receiving dialysis,
with nearly half of the participants in the EVOLVE trial evaluated (7,8). The hypothesis that SNPs in CASR
would be associated with responsiveness to cinacalcet was on the basis of the allosteric activation of the
receptor by cinacalcet. A previous study of seven patients undergoing hemodialysis demonstrated that one
patient homozygous for the missense CASR allele (rs1042636) had a more dramatic PTH lowering response
to cinacalcet (13). We found an association of this same SNP with baseline PTH in the EA population, but
did not find any association with change in PTH. However, we did identify another SNP, rs9740, located in
the 3′ untranslated region to be marginally associated with an interaction between the SNP and change in
calcium with cinacalcet in both the AfAn and EA populations. As shown in Figure 2, C and D, the
difference in the percent decrease in calcium in response to cinacalcet in the AA and AG/GG genotype is
4% and 2%, respectively. These results suggest a possible role of polymorphisms in the CASR gene in the
hypocalcemic response to cinacalcet.
The CASR gene is a member of the superfamily of G-protein coupled receptors with a very large
extracellular domain, seven membrane spanning segments, and a relatively large cytoplasmic domain.
Extracellular calcium binds to multiple sites on the receptor, leading to conformational changes that result
in activation of cell signaling and suppression of PTH secretion (21). Over 400 mutations in the gene have
been identified throughout the receptor (http://www.casrdb.mcgill.ca/). The more severe phenotypes of
autosomal dominant familial hypocalciuric hypercalcemia and autosomal recessive neonatal severe
hyperparathyroidism are because of inactivating mutations; activating mutations can lead to autosomal
dominant hypocalcemia (reviewed in Pollak et al. [22]).
Multiple studies have demonstrated an association of SNPs in the CASR with serum calcium
concentrations. Scillitani et al. (23) in a cohort of 377 Italian participants without CKD found that variants
in the same three missense CASR SNPs examined in this study were responsible for 16.5% of the variance
in serum ionized calcium. Homozygosity for the major allele in rs1801725 and rs1801726 was associated
with higher ionized calcium, whereas homozygosity for the major allele in rs1042636 was associated with
lower ionized calcium. In one genome-wide association study, rs1801725 was associated with 1.26% of the
serum calcium variance in EA, and rs17251221 (in high LD with rs1801725) was also associated with
2
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serum calcium in Asian Indians (24). A more recent genome-wide association study in EA reported
genome-wide significant association of serum calcium with rs73186030, also in high LD with rs1801725
(25). Additional studies also found association of rs1801725 with serum calcium in Canadian women (14)
and a white cohort from the Atherosclerosis Risk in Communities study (26). In this study, we also detected
association of rs1801725 with serum calcium, in addition to associations of these missense SNPs with
baseline PTH in the EA population. The association of these SNPs with PTH, in addition to calcium, may
be because of the many factors that alter the calcium–PTH relationship in patients with CKD-MBD. The
MAF for all three of these missense mutations was also low, especially in those of AfAn, likely limiting the
power for detecting stronger associations with serum calcium. A modest association was also identified
with the CASR SNPs and baseline calcium and FGF23 levels in the AfAn population for intronic SNPs,
reflecting likely epigenetic effects, although these have not been elucidated for the CASR gene to date (27)
We found different associations of the SNPs in CASR in the EA and AfAn populations. In the EA
population, baseline serum PTH, BALP, and phosphate were associated with missense SNPs. In contrast, in
the AfAn population, baseline serum calcium, and FGF23 were associated with intronic CASR SNPs. This
could be due, in part, to differences in phenotype by race or to differences in allele frequencies for most of
the SNPs between the EA and AfAn populations, with the minor allele being different for rs1393199. In
patients receiving hemodialysis, AfAn patients generally have higher PTH compared with EA patients at
similar levels of bone turnover (28). Another study found that optimal PTH targets for bone remodeling
may be different in EA and AfAn patients (29). Among participants in the Chronic Renal Insufficiency
Cohort study, black participants had higher concentrations of serum phosphate, alkaline phosphatase,
FGF23, and PTH, and lower 24-hour urinary excretion of calcium and phosphorus (10). These differences
suggest that differences in CASR polymorphisms may contribute to phenotypic differences in CKD-MBD
in EA and AfAn populations.
Our study identified an association with a group of intronic SNPs in high LD in the CASR gene and a
higher risk of fracture in the EA population that was attenuated with cinacalcet treatment. The consistency
of these results across SNPs in high LD increases the confidence in our findings. To our knowledge, no
study has previously identified an association with these SNPs and fracture, and thus the results must be
validated. In the EVOLVE trial, clinically symptomatic adjudicated fractures were found in 13% of the
participants during the study, and were reduced with cinacalcet treatment (20). However, only 15.6% of the
fractures were hip fractures (20). Unfortunately, the majority of cohort studies that may have access to
DNA samples have only assessed hip fracture, and thus our results may not be readily validated. The CASR
gene is important in fetal bone development; conditional deletion of CASR in early osteoblasts leads to
altered bone phenotype, although the results vary depending on the construct used (30). Other studies also
suggest a regulatory role of calcium in PTH-induced bone resorption and formation (31) and regulation of
FGF23 secretion (32,33), but whether this is mediated by CASR is not yet known. Taken together, these
results suggest that further exploration of the role of CASR polymorphisms on calcium sensing by
osteoblasts and the function of the receptor in bone is warranted.
This study has both strengths and weaknesses. First, it is the largest genetic study in patients on dialysis to
date. Second, SNPs across the CASR gene were evaluated, including missense and intronic SNPs
previously reported in the literature. Third, a comprehensive set of CKD-MBD manifestations were tested
for association with these SNPs. One weakness of the study is the modest sample size, although it is the
study with the largest sample size examining SNPs and mineral metabolism to date. Thus, some
associations may have been missed, particularly in the smaller AfAn population. To ensure complete
coverage of CASR, a dense set of SNPs were genotyped. Because of the LD among these SNPs, we did not
correct for the number of SNPs genotyped. Thus, some results could be potential false positive results.
Although only clinical characteristics known to be affected by polymorphisms in the CASR gene were
tested, these results need to be replicated in independent samples.
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In summary, we identified several SNPs in CASR that were associated with baseline biochemical values of
CKD-MBD, with distinct differences in EA and AfAn populations but no association with VDR. Of
importance, only one SNP, rs9740, showed an interaction between decrease in corrected serum calcium and
treatment with cinacalcet in both populations. An additional observation of an association between a group
of intronic SNPs in high LD and risk of fracture in the EA population requires further validation. These
associations, if validated, may partly explain differences in the clinical manifestations of CKD-MBD
between EA and AfAn populations, and in the biochemical response to cinacalcet in many patients.
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Figure 1.
Open in a separate window
Linkage disequilibrium (LD) maps for the calcium-sensing receptor (CASR). LD maps for the CASR single nucleotide
polymorphisms (SNPs) examined in (A) the European ancestry population and (B) the African ancestry population.
Numeric values represent pairwise LD as measured by r . SNPs in high LD are represented by darker squares.2
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Table 1.
Demographic and baseline laboratory values for DNA cohort compared with the primary EVOLVE
trial (7,8,33,34)
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Characteristic All, n=1812 EA, n=1067 AfAn, n=405 EVOLVE Cohort,
n=3883
Cinacalcet use, n (%) 918 (50.7) 551 (51.6) 203 (50.1) 970 (50.7)
Demographics
Age, yr, mean (SD) 54.3 (14.1) 56.4 (14.0) 52.2 (13.4) 54.4 (14.4)
Sex, women, n (%) 718 (39.6) 406 (38.0) 171 (42.2) 1578 (40.6)
Ethnicity, n (%)
 EA 1067 (58.9) 2241 (57.7)
 AfAn 405 (22.3) 837 (21.6)
 Other 340 (18.8) 805 (20.7)
Dialysis vintage, mo 45.0 (9.0; 146.0)
 <2 yr, n (%) 527 (29.1) 315 (29.5) 138 (34.1)
 2 to <5 yr, n (%) 601 (33.2) 340 (31.9) 141 (34.8)
 ≥5 yr, n (%) 684 (37.7) 412 (38.6) 126 (31.1)
Diabetes, type 1 or 2, n (%) 588 (32.5) 295 (27.6) 181 (44.7) 1302 (33.5)
History of parathyroidectomy, n (%) 93 (5.1) 64 (6.0) 9 (2.2) 176 (4.5)
History of fracture, n (%) 349 (19.3) 214 (20.1) 70 (17.3) 769 (19.8)
Baseline drug use
 Calcium-based phosphate binders, n (%) 1014 (56.0) 669 (62.7) 150 (37.0) 2025 (59.8)
 Baseline vitamin D, n (%) 1134 (62.6) 650 (60.9) 314 (77.5) 2232 (57.5)
Baseline laboratory values
 Corrected calcium, mg/dl, mean (SD) 9.8 (0.70) 9.8 (0.70) 9.8 (0.59) 9.8 (0.7)
 Phosphorus, mg/dl, mean (SD) 6.5 (1.4) 6.6 (1.5) 6.3 (1.4) 6.5 (1.4)
 Intact PTH, pg/ml, median (p10; p90) 691 (363;
1662)
720 (370;
1702)
611 (337;
1410)
691.8 (363.0;
1694.0)
 FGF23, pg/ml, median (p10; p90) 5670 (300;
18,240)
5970 (320;
19,105)
5080 (350;
17,000)
5590 (580; 19,540)
 Bone alkaline phosphatase, µg/L,
median (p10; p90)
22.3 (11.0;
62.2)
21.2 (10.6;
57.5)
22.9 (11.3;
60.1)
23.0 (11.5; 68.1)
 N-telopeptide, nmol BCE/L, median
(p10; p90)
249 (76; 815) 251 (75; 803) 227 (67; 628) 255 (80; 884.9)
 1,25 dihydroxy vitamin D level, ng/ml,
median (p10; p90)
16 (8; 33) 16 (8; 32) 13.0 (7; 25) 17.0 (8; 37)
Percent change in laboratory values
 Percent change in corrected calcium,
mean (SD)
−4.2 (8.8) −4.6 (8.8) −3.3 (8.4)
 Percent change in PTH, median (p10;
p90)
−23.5 (−77.1;
39.6)
−25.2 (−78.7;
36.5)
−27.7 (−74.3;
43.1)
 Percent change in FGF23, median (p10;
p90)
−23.8 (−80.4;
93.0)
−24.6 (−79.8;
85.9)
−21.4 (−80.7;
137.2)
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Characteristic All, n=1812 EA, n=1067 AfAn, n=405 EVOLVE Cohort,
n=3883
 Percent change in phosphorus, mean
(SD)
−8.2 (23.2) −8.6 (22.2) −7.3 (25.7)
Open in a separate window
EVOLVE, Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events; EA, European ancestry; AfAn,
African ancestry; PTH, parathyroid hormone; p10, 10th percentile; p90, 90th percentile; FGF23, fibroblast growth
factor 23.
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Table 2.
Associations of CASR single nucleotide polymorphisms with baseline biochemistries in European
ancestry
SNP Function MAF Calcium PTH FGF23 BALP Phosphorus
P Value P
Value
β 95%
CI
P
Value
P
Value
β 95%
CI
rs6776158 5′ 0.36 0.74 0.75 0.56 0.10 0.51
rs937627 Intron 0.23 0.69 0.44 0.71 0.50 0.86
rs11711698 Intron 0.35 0.72 0.15 0.45 0.16 0.78
rs4678044 Intron 0.17 0.33 0.68 0.32 0.50 0.54
rs4300957 Intron 0.17 0.59 0.63 0.10 0.57 0.59
rs2134223 Intron 0.12 0.53 0.52 0.42 0.02 0.07 0.01
to
0.13
0.81
rs7635128 Intron 0.12 0.60 0.54 0.35 0.01 0.08 0.02
to
0.14
0.98
rs7647446 Intron 0.17 0.49 0.53 0.10 0.53 0.60
rs937626 Intron 0.29 0.91 0.94 0.51 0.02 0.05 0.01
to
0.10
0.69
rs3828359 Intron 0.05 0.17 0.09 0.94 0.84 0.57
rs2036399 Intron 0.14 0.38 0.54 0.62 0.98 0.59
rs1393199 Intron 0.30 0.90 0.45 0.59 0.55 0.80
rs7652858 Intron 0.05 0.17 0.09 0.93 0.83 0.56
rs1801725 Missense
A986S
0.16 0.57 0.02 0.06 0.01 to
0.11
0.20 0.58 0.03
rs1042636 Missense
R990G
0.07 0.11 0.01 −0.10 −0.16
to
−0.03
0.14 0.20 0.41
rs1801726 Missense
E1011Q
0.05 0.17 0.09 0.94 0.84 0.57
rs6438718 3′ 0.00
rs9740 3′ 0.36 0.42 0.69 0.71 0.84 0.54
P values for each clinical phenotype are presented for each SNP for EA participants. β values and 95% CIs are
provided for SNPs with P<0.05. The direction of β reflects the effect of one copy of the minor allele. The calcium was
corrected for albumin. Covariates for calcium were baseline calcium binder use, age, PTH, phosphorus, NTX, and
bone alkaline phosphorus. Covariates for PTH were age, bone alkaline phosphorus, NTX, baseline vitamin D use, and
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calcium. Covariates for FGF23 were age, sex, dialysis duration, bone alkaline phosphorus, calcium, phosphorus, and
PTH. Covariates for phosphorus were age, bone alkaline phosphorus, calcium, PTH, and baseline vitamin D use.
Covariates for bone alkaline phosphorus were age, sex, dialysis duration, PTH, and NTX. Blank cells are due to
MAF<0.05. CASR, calcium-sensing receptor; SNP, single nucleotide polymorphism; MAF, minor allele frequency;
PTH, parathyroid hormone; FGF23, fibroblast growth factor 23; BALP, bone-specific alkaline phosphatase; 95% CI,
95% confidence interval; NTX, N-telopeptide; EA, European ancestry.
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Table 3.
Associations of CASR single nucleotide polymorphisms with baseline biochemistries in African
ancestry
SNP Function MAF Calcium PTH FGF23 BALP Phosphorus
P
Value
β 95%
CI
P
Value
β 95%
CI
P
Value
P
Value
β 95%
CI
rs6776158 5′ 0.39 0.63 0.34 0.33 0.89 0.62
rs937627 Intron 0.09 0.17 0.40 0.23 0.65 0.83
rs11711698 Intron 0.17 0.89 0.95 0.55 0.28 0.02 −0.04 −0.08
to
−0.01
rs4678044 Intron 0.15 0.23 0.46 0.16 0.46 0.80
rs4300957 Intron 0.11 0.01 −0.02 −0.03
to
−0.01
0.76 0.04 0.23 0.01
to
0.45
0.65 0.99
rs2134223 Intron 0.16 0.09 0.27 0.29 0.87 0.03 0.04 0.003
to
0.08
rs7635128 Intron 0.22 0.02 0.01 0.002
to 0.02
0.89 0.94 0.77 0.47
rs7647446 Intron 0.14 0.04 −0.01 −0.02
to
−0.001
0.79 0.01 0.26 0.05
to
0.46
0.50 0.63
rs937626 Intron 0.37 0.77 0.66 0.12 0.33 0.32
rs3828359 Intron 0.18 0.65 0.56 0.11 0.22 0.09
rs2036399 Intron 0.14 0.71 0.74 0.40 0.59 0.97
rs1393199 Intron 0.26 0.59 0.50 0.21 0.15 <0.001 0.05 0.02
to
0.08
rs7652858 Intron 0.17 0.67 0.57 0.20 0.12 0.07
rs1801725 Missense
A986S
0.04
rs1042636 Missense
R990G
0.05 0.70 0.35 0.41 0.32 0.06
rs1801726 Missense
E1011Q
0.17 0.67 0.57 0.20 0.12 0.07
P values for each clinical phenotype are presented for each SNP for AfAn participants. β values and 95% CIs are
provided for SNPs with P<0.05. The direction of β reflects the effect of one copy of the minor allele. The calcium was
corrected for albumin. Covariates for calcium were baseline calcium binder use, age, PTH, phosphorus, NTX, and
dialysis duration (AfAn). Covariates for PTH were age, bone alkaline phosphorus, baseline vitamin D use, and
Calcium-Sensing Receptor Genotype and Response to Cinacalcet in Patie... https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5498355/?report=printable
17 of 20 5/24/2019, 3:32 PM
calcium. Covariates for FGF23 were age, sex, dialysis duration, bone alkaline phosphorus, calcium, phosphorus, and
NTX. Covariates for phosphorus were age, bone alkaline phosphorus, calcium, PTH, and NTX. Covariates for bone
alkaline phosphorus were age, sex, dialysis duration, PTH, baseline vitamin D use, and baseline calcium binder use.
Blank cells are due to MAF<0.05. CASR, calcium-sensing receptor; SNP, single nucleotide polymorphism; MAF,
minor allele frequency; PTH, parathyroid hormone; FGF23, fibroblast growth factor 23; BALP, bone-specific alkaline
phosphatase; 95% CI, 95% confidence interval; NTX, N-telopeptide; AfAn, African ancestry.
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Figure 2.
Association of CASR SNPs and percent change in biochemical measures from baseline to week 20. (A) Association of
the CASR SNP rs937627 with percent change in PTH in the EA population, adjusted for baseline PTH, and age,
demonstrating an association with genotype (P<0.05) but no interaction with treatment (P=0.06). (B) Association of the
CASR SNP rs2036399 with percent change in FGF23 in the AfAn population, adjusted for baseline FGF23 and age. The
results demonstrate no association with genotype (P=0.34) but an interaction with treatment (P<0.02). Homozygotes for
the minor allele had a greater reduction in FGF23 with cinacalcet. (C) EA population and (D) AfAn population association
of the CASR SNP rs9740 with percent change in calcium adjusted for age, baseline calcium, duration dialysis, baseline
bone alkaline phosphatase in EA, and baseline calcium and age in AfAn. In the EA population, there was no association
with genotype (P=0.89), but there was a treatment-by-genotype interaction in that homozygotes for the major allele had a
greater decrease in response to cinacalcet (P=0.03). In the AfAn population, there was no main effect of genotype
(P=0.06) but a treatment-by-genotype interaction (P=0.02). Gray bars. Genotype; Black bars, participants in the EVOLVE
trial randomized to placebo; hashed bars, participants in the EVOLVE trial randomized to cinacalcet. AfAn, African
ancestry; CASR, calcium-sensing receptor; EA, European ancestry; EVOLVE, Evaluation of Cinacalcet HCl Therapy to
Lower Cardiovascular Events; FGF23, fibroblast growth factor 23; PTH, parathyroid hormone; SNP, single nucleotide
polymorphism.
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Figure 3.
Association of CASR SNP rs7647446 with incidence of fracture during the Evaluation of Cinacalcet HCl Therapy to
Lower Cardiovascular Events (EVOLVE) trial. Association of genotype and genotype-by-treatment interaction and any
type of fracture during the EVOLVE trial. The results demonstrate that there is a modest but nonsignificant increased
association with a higher incidence of fracture with increased number of minor A alleles (P=0.08), and that the number of
fractures is reduced when the individuals are treated with cinacalcet (P=0.03). Similar results were observed with other
single nucleotide polymorphism in high linkage disequilibrium with rs7647446. Gray bars, genotype; black bars,
participants in the EVOLVE trial randomized to placebo; hashed bars, participants in the EVOLVE trial randomized to
cinacalcet.
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